Cited 9 times in
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.